Quarterly revenue came in modestly ahead of expectations, but not enough to change the broader setup. Q2 total net revenue was $266.0 million versus a published consensus of approximately $260.1 million, while adjusted non-GAAP EBITDA reached $71.6 million, up 32% year over year. The filing does not provide reported adjusted EPS in the presentation, so an EPS beat or miss cannot be assessed. (Q2 2026 and recent business highlights)
| Metric | Q2 2026 | Q2 2025 | Change / expectation |
|---|---|---|---|
| Total net revenue | $266.0M | $211.4M | +26%; versus consensus of ~$260.1M |
| Rare Disease and Brands revenue | $165.4M | $117.2M | +41% |
| Generics and Other revenue | $100.7M | $94.2M | +7% |
| Adjusted non-GAAP EBITDA | $71.6M | $54.1M | +32% |
| 2026 total net revenue guidance | $1,080M–$1,140M | — | Reaffirmed |
| 2026 Cortrophin Gel revenue guidance | $520M–$540M | — | Reduced from $540M–$575M |
| 2026 adjusted non-GAAP EBITDA guidance | $285M–$300M | — | Reaffirmed |
| 2026 adjusted non-GAAP diluted EPS guidance | $9.19–$9.69 | — | Reaffirmed |
The key change is a cut to the lead growth asset, not a clean guidance reaffirmation. ANI kept total revenue, EBITDA, EPS, ILUVIEN, and gross-margin targets unchanged, but lowered Cortrophin Gel revenue guidance from $540–$575 million to $520–$540 million. Because Cortrophin is positioned as the main driver of the Rare Disease transformation, the reduction is more meaningful than the headline “reaffirming guidance” suggests. (Reaffirming 2026 Financial Guidance)
The quarter’s strength was broad, but the quality of the beat is partly helped by licensing revenue. Rare Disease and Brands revenue rose 41% year over year and generics increased 7%, indicating that the quarter was not dependent on a single reported segment. However, ANI recognized an $8 million Harmony Biosciences development milestone in Q2, with another $2 million expected in Q3; that contribution is non-recurring and makes the underlying run-rate somewhat less impressive than the headline EBITDA growth implies. (Establishing collaborations to drive future value for our stakeholders)
Gout expansion is an encouraging offset, but it is still early evidence rather than delivered revenue. The new sales team was fully operational only at the end of June, and ANI reported that more than 95% of representatives were generating multiple new patient cases by the end of July, with more than one-third of prescribers initiating at least two cases. Those metrics support future Cortrophin adoption, but they do not yet explain away the lower Cortrophin revenue target. (Encouraging early signals from gout expansion team)
Net read: a modest quarterly beat is outweighed by the quieter warning in Cortrophin guidance. Generics, cash generation, and the broader full-year profit framework remain intact, but the lowered forecast for ANI’s strategic centerpiece signals that near-term Cortrophin ramp expectations are less aggressive than previously assumed. That makes the filing slightly worse than the market’s standing expectation, despite solid Q2 growth.
Read the original 8-K on SEC EDGAR ↗